Kornimate/medical-research-clean huggingface dataset:
effects of acute intermittent hypoxia on sensory function in healthy adults

Conditions: Sensitivity

Summary: exposure to acute intermittent hypoxia (aih) can facilitate of motor output but no studies of sensory effects has been reported.

despite the strong results of motor studies, the affects of aih on sensory function has not been established. we will use a commercially-available hypoxicator that can be programmed to achieve a targeted level of arterial oxygen saturation. we plan to compare 3 previously published protocols that have generated motor facilitation (and a sham condition) to characterize and effects on sensory function in healthy adults.

Eligibility criteria:
inclusion criteria: * 18 to 40 years of age exclusion criteria: * diagnosis of cardiovascular disease (hypertension, arrhythmias, coronary artery disease, congenital and valvar heart diseases) * diagnosis of neuromuscular disease * diagnosis of any neurological disease * presence of concurrent medical illness including infection, fractures * diagnosis of obstructive sleep apnea * diagnosis of obstructive/restrictive lung disease * diagnosis of exercise induced asthma * fev1/fvc\<80% and/or fvc\<80% of predicted value indicating airway obstruction * subjects on prednisolone therapy or selective serotonin reuptake inhibitor (ssri) therapy will be excluded from the study as these pharmacological agents are known to amplify the effects of ih\[22, 23\] * diagnosis of epilepsy or history of seizures and attention deficit disorders * pregnancy * diabetes * history of coagulation disorders * history of chronic pain * body mass index(bmi)\> 35kg/m2 * subjects on prescription medicines such as beta blockers and other drugs that are prescribed in any of the exclusionary disorders listed above.

Keywords: thermal threshold pressure pain threshold temporal summation
evaluation of the nonmotor symptomatology of parkinsonian patients treated with two strategies related to apomorphine pump therapy in french hospitals

Conditions: Parkinson Disease

Summary: there is currently no consensus on the adequate concomitant treatment to apomorphine pump in parkinson's disease (pd). in practice, some centers withdraw all dopaminergic agonists when initiating apomorphine pump therapy, whereas others combine the two. to date, there has been no study led to determine the best strategy for efficiently treating motor and nonmotor symptoms, as well as improving patients' quality of life (qol). this preliminary study, entitled agapo, aims at identifying significant differences in patients' evolution (nonmotor symptoms and quality of life), over a course of 6 months, depending on the two strategies adopted in french centers (apomorphine pump with or without dopaminergic agonists), through the non motor symptoms scale (nmss, chaudhuri et al, 2017).

the recruitment period will be 24 months. the duration of the study will be 6 months for each patient due to adjustments of apomorphine pump parameters and oral medication as well time needed for motor and nonmotor changes to develop and influence qol. this study will be done without any modification of the planned treatment plan for each patient included. the treatments are administered in accordance with their marketing authorization and according to the usual practices of each center. no additional visits are expected.

Eligibility criteria:
inclusion criteria: * adults aged = or \> 18 years, * idiopathic pd (according to british brain bank criteria) without any other known or suspected cause of symptoms, * indicated for apomorphine pump therapy and according to the centers' practice, treatment with apomorphine pump association with dopamine agonists or apomorphine pump therapy alone * presence of fluctuations for \> 3 years, * patients covered with social insurance. * written informed consent exclusion criteria: * neurological (other than parkinson's disease) or severe psychiatric history (depression, schizophrenia, addiction, bipolar disorder, anxiety and depressive disorders); * severe neurocognitive disorders (dsm-v) * history of use of apomorphine pump treatment or deep brain stimulation or lesional surgery for pd or intrajejunal l-dopa; * history or current drug or alcohol abuse or dependencies; * history of impulse control disorders; * adults legally protected (under judicial protection, guardianship or supervision), persons deprived of their liberty; * inability to understand the information given on the study, to express informed consent.

Keywords: parkinson nonmotor symptomatology
long-term efficacy in amd of rheopheresis in north america

Conditions: Macular Degeneration

Summary: the purpose of these studies are to evaluate the effect on vision in subjects with amd who received active and placebo treatment in the mira-1 study.


Eligibility criteria:
inclusion criteria: * must have participated in treatment arm of mira-1 trial and completed 4 treatments and 6 and 9 month follow up visits. * dry amd in at least one eye. * available for study duration of 12 months. * weigh \>110 lbs. * if on lipid-lowering medication must remain on for duration of trial. if not, must agree to not initate during trial. * normal pt/ ptt. if on coumadin, at the discretion of the investigator. * must be highly motivated, alert and oriented, and able to provide consent. * agree to discontinue current ocular vitamin regimen and take uniform supplement provided by the sponsor. exclusion criteria: * both eyes wet amd. * condition limiting view of the fundus. * poor general health or unstable diseases. * hct \< 35%, evidence of active bleeding, platelet count \<100000 k/ul, prolonged pt/ ptt, or significant coagupapathies. * significant cardiac problems. * uncontrolled hypertension. * history of cva of tia within a year. * significant hepatic, renal, or pulmonary disease, or insulin dependent diabetes. * allergy to fluorescein sodium and indocyanine green (icg), heparin, acda, local anesthetics, or adhesive tape. * pregnant or breastfeeding women, or women of childbearing potential not using chemical or mechanical contraception. * investigation trial within 30 days. * major surgery within 30 days. * unwilling to adhere to visit schedule. * unstable medical of psychological condition.

Keywords: amd macular degeneration retinal degeneration
imagery ability in obstetric brachial plexus palsy

Conditions: Brachial Plexus Palsy; Image, Body

Summary: obstetric brachial plexus palsy (obpp) is the paralysis of the ipsilateral upper extremity after a brachial plexus injury that occurs during labor. imagery is to rehearse sensorial experiences in the mind such as auditory, visual, tactile, olfactory, gustatory or kinesthetic sensation. imagery is used as a new technique in rehabilitation recently. various studies have reported the importance of imagery and using imagery as a rehabilitation technique in different neurologic and orthopedic conditions. this study aimed to evaluate imagery ability in children with obpp.


Eligibility criteria:
inclusion criteria: * ages between 8-18 years * children with obpp narakas's classification system rating of type 1, type 2a, type 2b, or type 3 * standardized mini-mental state examination score \>24 * with no physical or neurological condition affecting motor development exclusion criteria: * narakas's classification system rating of type 4 * standardized mini-mental state examination score \<24 * surgical operation in last 6 months * physical or neurological conditions * refuse to attend to the study

Keywords: brachial plexus imagery body image sensation questionnaires
gandouling in the treatment of wilson's disease

Conditions: Wilson's Disease

Summary: to evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of wilson's diasease.

to evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of wilson's diasease.test various indicatorsbefore test, 4 weeks, 12 weeks and 24 weeks.

Eligibility criteria:
inclusion criteria: * comply with the diagnosis of wilson's disease "guidelines for diagnosis and treatment of wilson's disease 2021" * the diagnosis of tcm syndromes complies with the syndrome of phlegm and blood stasis; other copper-removing drugs * patients who have been treated with complexing agents for copper-removing treatment can enter the study after a 2-week washout period * age ≥15 years * informed consent of patients or legal representatives, and sign the informed consent form. exclusion criteria: * severe cerebral wd patients: obvious torsion spasm, dysphagia, or bed rest and other severe neurological impairment will interfere with the safety of the subjects (uwdrs part i neurological function score ≥156 points) * severe liver type wd patients: decompensated liver cirrhosis or liver cancer, manifested as portal hypertension, ascites, splenomegaly (wbc\<3.0\*109/l, plt\<50\*1012/l), esophageal varices, gastrointestinal bleeding, moderate to severe anemia or hepatic encephalopathy; severe liver fibrosis shown by imaging or any laboratory abnormality (uwdrs liver function score ≥ 17 points) * moderate to severe depression, recent suicidal thoughts or behavior, severe psychiatric symptoms (uwdrs part iii psychiatric symptom score ≥ 54 points) * history of epileptic seizures within 6 months * complicated with serious diseases such as brain tumors, brain trauma, blood diseases, cardiogenic diseases, hiv, etc. * nephritis, nephrotic syndrome, or kidney disease stage 3 or more * pregnant, planned pregnancy or breastfeeding women * cognitive dysfunction mmse≤26 points * those who are currently participating in other clinical trials * cannot comply with the follow-up plan
preoperative rehabilitation for patients undergoing surgery for lumbar spinal stenosis

Conditions: Lumbar Spinal Stenosis

Summary: the purpose of the present study is to evaluate the effectiveness of a prehabilitation program on the recovery of patients undergoing a minimally invasive surgery for degenerative lumbar spinal stenosis. to do so, 40 participants will be recruited and randomized into two groups; intervention or control group. participants in the intervention group will take part in a physical training program, three times a week for six weeks before undergoing surgery. the exercise program will be supervised and will aim at improving core muscles strength and endurance as well as spine stability. it is hypothesized that the prehabilitation program will significantly improve disability and pain intensity reported by patients after surgery. ultimately, this study aims to improve health care of patients awaiting lumbar surgery but its results may also impact the management of patients awaiting spine surgery for various conditions.


Eligibility criteria:
inclusion criteria: to be affected by degenerative lumbar spinal stenosis and to be awaiting minimally invasive surgery for the lumbar spinal stenosis exclusion criteria: non-degenerative spinal stenosis, arthritic conditions (except for facet arthrosis), impaired cognitive function, spinal instability and disagreement from the treating neurosurgeon for the patient to take part in the preadaptation programme.

Keywords: preoperative rehabilitation minimally invasive surgery functional capacity
neural response to food stimuli: fmri changes following cognitive behavioral therapy for binge eating disorder

Conditions: Binge Eating Disorder; Overweight and Obesity

Summary: the purpose of this research is to conduct a randomized controlled trial (rct) assessing the impact of cbt on neural responses to binge eating stimuli.

females with a bmi\>/=25 kg/m2 and bed will be randomized to either a 16-week, one-on-one cbt intervention (n=20) or a waitlist control (wl; n=20). both groups will have blood oxygen level-dependent (bold) functional magnetic resonance imaging (fmri) scans at baseline and after the 16-week intervention. during the scans, participants will complete the following tasks: 1) food-specific stop signal task (sst), and 2) script-driven imagery of binge foods.

Eligibility criteria:
inclusion criteria: 1. women who meet the dsm-5 criteria for bed as diagnosed by the eating disorder examination interview 2. ages 18 to 45 years of age 3. bmi \>/=25 kg/m2 4. premenopausal 5. able to provide informed consent 6. right-handed 7. eligible female patients will be: * non-pregnant, evidenced by a negative urine dipstick pregnancy test * non-lactating * surgically sterile or postmenopausal, or they will agree to continue to use an accepted method of birth control during the study 8. understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent exclusion criteria: 1. weight \> 158.8 kg (350 lbs, due to scanner weight restrictions) 2. supine abdominal width (with arms folded above) \> 70 cm or sagittal diameter \> 50 cm (due to scanner dimension restrictions) 3. pregnant or nursing (or plans to become pregnant in the next 5 months) 4. evidence of psychiatric disorder that significantly interferes with daily living 5. active suicidal ideation 6. type 1 diabetes or type 2 diabetes or a1c \> 6.5% 7. use of weight loss medications or other agents known to affect body weight (e.g., oral glucocorticoids, second-generation antipsychotic medications) in the past 3 months 8. psychiatric hospitalization within the past 6 months 9. self-reported alcohol or substance abuse within the past 12 months, including at-risk drinking (current consumption of ≥ 14 alcoholic drinks per week) 10. self-reported use of illicit drugs within the past 30 days 11. presence or history of orthopedic circumstances, metallic inserts, pacemaker, claustrophobia, or other conditions that may interfere with magnetic resonance imaging 12. loss of ≥ 10 lb of body weight within the past 3 months 13. history of (or plans for) bariatric surgery 14. visual, auditory, or other impairment that would affect task performance 15. epilepsy or other brain injury 16. participation in individual psychotherapy for bed in the prior 3 months 17. inability to attend treatment and lack of capacity to provide informed consent 18. any serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the study

Keywords: binge eating disorder obesity cognitive behavioral therapy
testicular cancer and aerobic and strength training

Conditions: Testicular Neoplasms

Summary: the present study examine the effects of an aerobic and strength training program on cardiorespiratory fitness in testicular cancer (tc) patients during chemotherapy. half of the participants will receive the exercise program and the other half will receive one individual lifestyle counseling session. the investigators hypothesize that tc patients in the exercise group will have less reduction in cardiorespiratory fitness during chemotherapy treatment compared to patients in the control group.

testicular cancer (tc) patients receiving chemotherapy often experience troublesome side-effects during and after treatment. both aerobic and strength exercise have showed beneficial effects on side-effects during and after treatment in other cancer diagnosis. knowledge of the effects of physical exercise during and after chemotherapy in tc patients is insufficient and studies are needed. the primary aim is to examine the effects of physical exercise on cardiorespiratory fitness in tc patients during chemotherapy. secondary aims are to examine the effects of physical exercise on other secondary health outcomes during and three and twelve months after chemotherapy. the present study is a randomized controlled trial comparing a tailored exercise program consisting of aerobic and strength training during chemotherapy to a control group receiving one individual lifestyle counseling session during the first chemotherapy cycle. the tc patients will be included and assessed before the first cycle of chemotherapy and further assigned to either a exercise group or a control group. the intervention will last for 9 or 12 weeks (depending on the number of bleomycin, etoposide, cisplatin (bep)/etoposide, cisplatin (ep) cycles received) and it will consists of two-three one-hour sessions per week mostly supervised by a personal trainer. all variables will be assessed pre- and post-intervention, and at three and 12 months follow-up.

Eligibility criteria:
inclusion criteria: * testicular cancer with seminoma or non-seminoma * stage ii-iv * referred to chemotherapy (3-4 bep (bleomycin, etoposide and cisplatin)-cycles or 4 ep (etoposide and cisplatin) -cycles) with/without retroperitoneal lymph node dissection (rplnd) * satisfactory norwegian language skills * signed informed consent exclusion criteria: * severe brain and lung metastasis (reduced lung function) * heart and lung diseases that contraindicate exercise testing and the supervised exercise program without adjusted actions according to american college of sports medicine (acsm)'s guidelines) * physical and mental conditions of a severity that complicates the ability for exercise testing and the supervised exercise program

Keywords: testicular cancer physical exercise chemotherapy
sequence of radiation and targeted therapy in brain metastases

Conditions: The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases

Summary: the investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.


Eligibility criteria:
inclusion criteria: * had histologically proven primary cancer. * had newly diagnosed brain metastases in contrast-enhanced mri. * brain metastases focus should be measurable. * all the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors. * karnofsky performance score (kps) ≥60 or kps ≥40, but only caused by brain metastases. exclusion criteria: * patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail * patients with leptomeningeal metastases at first diagnosis. * had synchronous or metachronous malignancies that might affect survival. * had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures. * had incomplete sociodemographic and/or clinicopathologic baseline data

Keywords: brain metastases radiotherapy targeted therapy
a study of orforglipron (ly3502970) in participants with obesity or overweight and type 2 diabetes

Conditions: Obesity; Overweight; Type 2 Diabetes

Summary: the main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. this trial is part of the master protocol study j2a-mc-gzpo. participation in the study will last about 18 months.


Eligibility criteria:
inclusion criteria: * have body mass index (bmi) ≥25 kilograms per square meter (kg/m2) at screening * have type 2 diabetes * have hemoglobin a1c (hba1c) ≥7% and ≤10% at screening * have a history of at least one unsuccessful dietary effort to lose body weight exclusion criteria: * have type 1 diabetes * have an unstable body weight within 90 days prior to screening * have new york heart association functional classification iv congestive heart failure or an acute cardiovascular condition within 90 days prior to screening * have acute or chronic hepatitis or pancreatitis * are taking other medications or alternative remedies to manage weight loss
development of an adaptive treatment for weight loss in people with prediabetes

Conditions: PreDiabetes; Obesity

Summary: this 16-week study will use an experimental approach called the sequential multiple assignment randomized trial to help determine which combination and sequence of weight loss program features are most effective in people who are at risk for type 2 diabetes. participants in the study will be initially randomized to consume either a high or reduced carbohydrate diet. after 4 weeks, participants will be identified as responders (greater than or equal to 2.5% weight loss) or non-responders (less than 2.5% weight loss). responders will continue with their initial randomized group for the remainder of the trial. non-responders will be re-randomized to 2nd stage interventions of either including additional exercise counseling and training or beginning a time restricted eating protocol for the remainder of the trial.


Eligibility criteria:
inclusion criteria: * 18-75 years of age * bmi of 27 kg/m2 or greater * at risk for developing type 2 diabetes (prediabetes) exclusion criteria: * pregnant, planning to become pregnant, or breastfeeding * uncontrolled hypo or hyperthyroidism

Keywords: weight loss reduced carbohydrate diet exercise training time restricted eating
improving the early detection of cardiometabolic disease risk

Conditions: Metabolic Syndrome

Summary: the goal of this observational study is to reduce an individual's cardiometabolic disease risk by improving the ability to detect cardiometabolic disease risk in young adults through the use of novel technologies that increase access to and examine the utility of, a continuous metabolic syndrome severity score. an additional goal of this study is to understand the barriers to engagement in health-promoting behaviors and beliefs about interventions aimed at mitigating metabolic syndrome risk through a brief online lifestyle intervention. the main question\[s\] it aims to answer are: * can a smartphone-based imaging system accurately predict a continuous metabolic syndrome severity score, in addition to other markers of cardiometabolic disease, in young adults? * what is the relationship between autonomic dysfunction and metabolic syndrome severity in a cohort of young adults? * what is the relationship between peripheral vascular dysfunction and metabolic syndrome severity in a cohort of young adults? * what are the associations between metabolic syndrome severity and gait and functional ability in young adults using novel markerless motion capture technology? * what are the attitudes and barriers towards lifestyle interventions targeted to reduce metabolic syndrome severity? * what are the treatment-seeking and willingness to engage behaviors toward a webpage focused on lifestyle interventions to reduce metabolic syndrome severity? participants will be asked to undergo several assessments across four separate days which are design designed to determine the associations between cardiometabolic health markers and components of: * body composition * cardiovascular function * functional ability * attitudes and behaviors towards health-related interventions


Eligibility criteria:
inclusion criteria: - adults between the ages of 18-39 years of age exclusion criteria: * younger than 18 or older than 39 * pregnant * breastfeeding or lactating * missing any limbs or part of a limb * having a substantial amount of metal implants (metal plates or complete joint replacements) * having a pacemaker or any other electrical implant * type i diabetes * gestational diabetes * taking insulin * diagnosed heart failure, cardiomyopathy (dilated or hypertrophic), valvular disease * any history of severe traumatic brain injury or mild traumatic brain injury within the last two years * kidney disease * liver disease * thyroid disease * any diagnosed neurological or neurodegenerative diseases * having received ionizing radiation from a medical procedure within the last 30 days * being on a medically prescribed diet * having donated blood or plasma in the last 20 days prior to blood collection procedures * taking any supplements/medications that may interfere with the results of the study * any injury or physical impairment that would prevent performing any functional measures for this study